07 August 2013 | News | By BioSpectrum Bureau
Beijing King Health Investment will distribute Allium Medical's urinary tract stents for eight years in China
Singapore: Israel-based Allium Medical signed a strategic agreement with Beijing King Health Investment to exclusively distribute its urinary tract stents for eight years in China.
King Health will buy the stents during the contract period and sales will begin in 2016, subject to obtaining permits from the China Food and Drug Administration (CFDA).
Mr Asaf Alperovitz, CEO, Allium, said that, "The agreement with Beijing King Health is strategic and vital for the company, both in terms of potential revenue and profits, and because of the foothold in Far Eastern markets."